Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SSY Group ( (HK:2005) ) has issued an update.
SSY Group Limited has received approval from China’s National Medical Products Administration for the registration of its Metoclopramide and Metoclopramide Hydrochloride as bulk drugs used in market preparations. These dopamine D2 antagonists, which also act as 5-HT4 receptor agonists, are designed to enhance gastrointestinal motility and address conditions such as vomiting, nausea, bloating, belching, and gastroesophageal reflux.
The update signals further progress in SSY Group’s product pipeline and expands its presence in the gastrointestinal therapeutics segment within China’s pharmaceutical market. The approvals may strengthen the company’s role as a supplier of active ingredients for downstream drug formulations, potentially supporting broader adoption of its products among hospitals and other medical providers.
The most recent analyst rating on (HK:2005) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited is a Hong Kong-listed pharmaceutical group focused on developing, manufacturing, and supplying drug products and active pharmaceutical ingredients to the healthcare market. The company targets therapeutic areas with strong clinical demand in China, supporting hospitals and medical institutions with injectable and other dosage-form medications.
Average Trading Volume: 4,677,449
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$8.56B
For detailed information about 2005 stock, go to TipRanks’ Stock Analysis page.